Professor of Medicine and Faculty Dean, Harvard Medical School
Chief Academic Officer of Beth Israel Lahey Health
Cambridge (Massachusetts – US)
Gyongyi Szabo, MD, PhD is the Mitchell T. Rabkin, M.D. Chair, Professor of Medicine and Faculty Dean at Harvard Medical School and Chief Academic Officer at the Beth Israel Deaconess Medical Center and Beth Israel Lahey Health.
Dr. Szabo is a physician scientist and an internationally known expert in liver immunology and inflammation. Her laboratory studies the cellular and molecular mechanisms of inflammation and innate immunity in liver injury to identify potential therapeutic targets in MASLD, MetALD and ALD. Her investigations recently revealed the importance of micro-RNAs and extracellular vesicles in liver diseases and showed that exosomes can serve as biomarkers as well as vehicles of inter-cellular and inter-organ communication. Dr. Szabo’s group made the novel discovery that NLRP3 activation and the IL-1ß pathway are potential therapeutic targets in alcoholic hepatitis and MASLD. Her translational studies provided the basis for first-time clinical trials in alcoholic hepatitis. She conducted over 40 clinical trials in liver diseases and she serves on scientific advisory boards of numerous pharmaceutical industry partners. She is elected member of the Hungarian Academy of Sciences, and fellow of the AASLD, AGA and the American College of Physicians (ACP). Dr. Szabo is chair of the NIAAA Board of Advisors and serves on advisory boards of several leading academic institutions and pharmaceutical companies. Dr. Szabo served on the AASLD Governing Board and was President in 2015. She was the inaugural Editor-in-Chief of Hepatology Communications and also received the 2020 Distinguished Scientific Achievement Award from the American Liver Foundation.